Liminatus Pharma, Inc.
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date			2025-Jun-30	2025-Mar-31
Fiscal Period			Q2-FY2025	Q1-FY2025
Total Revenue
Cost Of Revenue
Gross Profit
Gross Margin
Operating Expenses			1,118,211$				909,218$
Operating Income			(1,118,211$)	(255$)			(909,218$)	(247$)
Other Income			1,207,115$	(327,271$)			(77,220$)	(1,753,731$)
Interest Income			24,383$				25,231$
Interest Expenses
Income Before Tax			113,287$	(327,526$)			(961,207$)	(1,753,978$)
Tax Expenses
Income from Continuing Operations			113,287$	(327,526$)			(961,207$)	(1,753,978$)
Income from Discontinued Operations
Consolidated Income			113,287$	(327,526$)			(961,207$)	(1,753,978$)
Net Income			113,287$	(327,526$)			(961,207$)	(1,753,978$)
Profit Margin
Earnings to Minority
Earnings to Common Shareholders			113,287$	(327,526$)			(961,207$)	(1,753,978$)
Earnings Per Share, Basic			0.00$	(3,275.26$)			(0.05$)	(17,539.78$)
Earnings Per Share, Diluted			0.00$	(3,275.26$)			(0.05$)	(17,539.78$)
Average Shares, Basic			23,301,178	100			17,500,000	100
Average Shares, Diluted			23,301,178	100			17,500,000	100
EBIT			113,287$	(327,526$)			(961,207$)	(1,753,978$)
EBITDA			113,287$	(327,526$)			(961,207$)	(1,753,978$)

• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation